The amyloidosis market was valued at USD 4.35 Billion in 2024 driven by innovations in treatment options across the 8 major markets. It is expected to grow at a CAGR of 6.40% during the forecast period of 2025-2034 and attain a market value of USD 8.09 Billion by 2034.
Base Year
Historical Year
Forecast Year
The rising incidence of amyloidosis, combined with advancements in targeted therapies and personalized medicine, is fueling market expansion. Biomarkers-based diagnostics and combination therapies are enhancing treatment effectiveness and improving patient outcomes, thereby, boosting market growth.
One of the major market trends includes surge in approvals for drugs and therapies by prominent regulatory authorities. In December 2023, AstraZeneca and Ionis secured FDA approval for Wainua (eplontersen) to treat hereditary transthyretin-mediated amyloidosis (hATTR-PN).
The United States leads the market, supported by a strong healthcare system, substantial R&D investments, and the presence of leading pharmaceutical companies advancing diagnostics and therapies for amyloidosis.
Amyloidosis is a rare condition caused by the abnormal buildup of amyloid proteins in tissues and organs, leading to dysfunction and failure. Key growth drivers include rising prevalence among aging populations and advancements in specialized therapies. Major market trends involve expedited drug development along with the adoption of personalized medicine, and combination treatments. Moreover, rising R&D investments and regulatory incentives are reshaping the therapeutic landscape significantly.
Rising Prevalence of Amyloidosis Drives Market Growth
The rising prevalence of systemic and localized amyloidosis, particularly among older adults, is a key growth driver. AL amyloidosis, representing 78% of cases, occurs at a rate of 1 case per 100,000 in Western countries, with approximately 1,275–3,200 new cases occurring annually in the United States. The increasing prevalence underscores the demand for improved diagnostics and novel treatments.
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Treatment Type
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by End User
Market Breakup by Region
Market Segmentation Based on Route of Administration to Witness Substantial Market Growth
Based on the route of administration, the market is divided into oral, parenteral, and others. Among these, the oral administration is expected to lead the market. Oral medications, such as transthyretin stabilizers (e.g., Tafamidis), offer ease of use, reducing the need for hospital visits, high patient compliance, and cost-effectiveness. It allows for convenient at-home treatment. In addition, oral therapies provide a less invasive and more scalable option for long-term management, ensuring better patient adherence and improved outcomes.
Based on region, the market report covers the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India. Among these, the United States is expected to lead the market due to its robust healthcare infrastructure and a strong presence of prominent pharmaceutical companies. The research and development activities in the pharmaceutical and biotechnology sectors are also contributing to significant growth in the region.
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Established in 1849 and headquartered in New York, USA, Pfizer is one of the key pharmaceutical companies. It has developed Vyndamax (tafamidis), a breakthrough therapy for transthyretin amyloidosis (ATTR)-slowing down the progression of the disease and improving the survival rate in hereditary and wild-type ATTR patients.
Founded in 1886 and headquartered in New Jersey, USA, Johnson & Johnson is a major healthcare player. Its subsidiary, Janssen Pharmaceuticals, developed Daratumumab (Darzalex), a monoclonal antibody that targets plasma cells, thereby reducing amyloid protein production and effectively treating light-chain (AL) amyloidosis.
Takeda, based in Tokyo, Japan, is an international biopharmaceutical leader, founded in 1781. Its products for AL amyloidosis treatment include Ninlaro (ixazomib). It aims to be less invasive by providing an oral option to improve patients' outcomes in combination.
Bristol-Myers Squibb Company, located in New York, USA, was established in 1887. It is focused on innovative therapies for people and engages in the development of immunomodulatory therapies and combination therapies for AL amyloidosis and utilizes its oncological and hematological experience to improve disease management and survival rates for patients.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include Amgen Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Sanofi, Alnylam Pharmaceuticals, Inc., and Prothena.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share